# GeneDx Holdings Corp.: overview

WGS · Nasdaq · CIK 1818331 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/wgs.md) · [Financials](/companies/wgs/financials.md) · [Filings](/companies/wgs/filings.md) · [Insiders](/companies/wgs/insiders.md)

Latest reported revenue: [$114.4m](/filings/0001628280-26-051878.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 3, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-051878).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [76.9](/filings/0001818331-25-000130.md) | [95.6 d](/filings/0001818331-26-000015.md) | [87.1](/filings/0001818331-26-000041.md) | [103](/filings/0001628280-26-051878.md) | [117](/filings/0001818331-25-000130.md) | [121 d](/filings/0001818331-26-000015.md) | [102](/filings/0001818331-26-000041.md) | [114](/filings/0001628280-26-051878.md) |
| Gross margin | % | [62.2%](/filings/0001818331-25-000130.md) | [69.2% d](/filings/0001818331-26-000015.md) | [67.1%](/filings/0001818331-26-000041.md) | [69.0%](/filings/0001628280-26-051878.md) | [72.4%](/filings/0001818331-25-000130.md) | [69.6% d](/filings/0001818331-26-000015.md) | [66.7%](/filings/0001818331-26-000041.md) | [68.4%](/filings/0001628280-26-051878.md) |
| Operating margin | % | [(10.1%)](/filings/0001818331-25-000130.md) | [9.2% d](/filings/0001818331-26-000015.md) | [(5.2%)](/filings/0001818331-26-000041.md) | [8.7%](/filings/0001628280-26-051878.md) | [(2.8%)](/filings/0001818331-25-000130.md) | [(11.8%) d](/filings/0001818331-26-000015.md) | [(56.2%)](/filings/0001818331-26-000041.md) | [(15.3%)](/filings/0001628280-26-051878.md) |
| Net margin | % | [(10.8%)](/filings/0001818331-25-000130.md) | [5.7% d](/filings/0001818331-26-000015.md) | [(7.5%)](/filings/0001818331-26-000041.md) | [10.5%](/filings/0001628280-26-051878.md) | [(6.5%)](/filings/0001818331-25-000130.md) | [(14.6%) d](/filings/0001818331-26-000015.md) | [(61.9%)](/filings/0001818331-26-000041.md) | [(15.5%)](/filings/0001628280-26-051878.md) |
| Diluted EPS | $ per share | [(0.31)](/filings/0001818331-25-000130.md) | not reported | [(0.23)](/filings/0001818331-26-000041.md) | [0.36](/filings/0001628280-26-051878.md) | [(0.27)](/filings/0001818331-25-000130.md) | not reported | [(2.16)](/filings/0001818331-26-000041.md) | [(0.60)](/filings/0001628280-26-051878.md) |
| Free cash flow | $m | [(5.0) d](/filings/0001818331-25-000130.md) | [(6.2) d](/filings/0001818331-26-000015.md) | [4.1](/filings/0001818331-26-000041.md) | [8.1 d](/filings/0001628280-26-051878.md) | [9.6 d](/filings/0001818331-25-000130.md) | [(7.4) d](/filings/0001818331-26-000015.md) | [(38.9)](/filings/0001818331-26-000041.md) | [(39.1) d](/filings/0001628280-26-051878.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [212](/filings/0001818331-23-000024.md) | [235](/filings/0001818331-24-000008.md) | [203](/filings/0001818331-26-000015.md) | [305](/filings/0001818331-26-000015.md) | [428](/filings/0001818331-26-000015.md) |
| Gross margin | % | [(7.8%)](/filings/0001818331-23-000024.md) | [(11.4%)](/filings/0001818331-24-000008.md) | [44.4%](/filings/0001818331-26-000015.md) | [63.6%](/filings/0001818331-26-000015.md) | [69.7%](/filings/0001818331-26-000015.md) |
| Operating margin | % | [(210.3%)](/filings/0001818331-23-000024.md) | [(284.5%)](/filings/0001818331-24-000008.md) | [(89.2%)](/filings/0001818331-26-000015.md) | [(7.6%)](/filings/0001818331-26-000015.md) | [(3.1%)](/filings/0001818331-26-000015.md) |
| Net margin | % | [(115.6%)](/filings/0001818331-23-000024.md) | [(233.9%)](/filings/0001818331-24-000008.md) | [(86.8%)](/filings/0001818331-26-000015.md) | [(17.1%)](/filings/0001818331-26-000015.md) | [(4.9%)](/filings/0001818331-26-000015.md) |
| Diluted EPS | $ per share | [(2.27)](/filings/0001818331-23-000024.md) | [(53.63)](/filings/0001818331-24-000008.md) | [(7.23)](/filings/0001818331-26-000015.md) | [(1.94)](/filings/0001818331-26-000015.md) | [(0.73)](/filings/0001818331-26-000015.md) |
| Free cash flow | $m | [(200)](/filings/0001818331-23-000024.md) | [(326)](/filings/0001818331-24-000008.md) | [(185)](/filings/0001818331-26-000015.md) | [(34.0)](/filings/0001818331-26-000015.md) | [14.3](/filings/0001818331-26-000015.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/wgs/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2022-04-29 | [Blackstone Tactical Opportunities Associates III - NQ L.P.](/insiders/1826419.md) | 10% owner | Purchase (P) | 14,735 | $4.00 | $58.9k | [Form 4](/filings/0000899243-22-016476.md) |
| 2022-04-29 | [Blackstone Tactical Opportunities Associates III - NQ L.P.](/insiders/1826419.md) | 10% owner | Purchase (P) | 50,402 | $4.00 | $201.6k | [Form 4](/filings/0000899243-22-016476.md) |
| 2022-04-29 | [Blackstone Tactical Opportunities Associates III - NQ L.P.](/insiders/1826419.md) | 10% owner | Purchase (P) | 2,434,863 | $4.00 | $9.7m | [Form 4](/filings/0000899243-22-016476.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Corvex Management LP](/funds/1535472.md) | 2026-06-30 | $328.5m | 4,784,570 |  | Added +1,556,421 |
| [Casdin Capital, LLC](/funds/1534261.md) | 2026-06-30 | $254.5m | 3,707,164 |  | Added +700,000 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $117.1m | 1,706,239 |  | Added +155,531 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $114.6m | 1,669,441 |  | Added +334,461 |
| [ARK Investment Management LLC](/funds/1697748.md) | 2026-06-30 | $110.5m | 1,610,189 |  | Added +285,606 |
| [WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC](/funds/1644956.md) | 2026-06-30 | $96.2m | 1,400,653 |  | Added +625,384 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $67.8m | 988,297 |  | Added +456,062 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $60.3m | 879,003 |  | Added +20,420 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $59.4m | 865,462 |  | Added +218,061 |
| [First Light Asset Management, LLC](/funds/1600004.md) | 2026-06-30 | $53.8m | 783,923 |  | Added +540,996 |

## Recent filings

[All 749 filings](/companies/wgs/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-03 | 16:19 ET | [10-Q](/filings/0001628280-26-051878.md) | Quarterly report, period 2026-06-30 | 0001628280-26-051878 |
| 2026-08-03 | 16:14 ET | [8-K](/filings/0001628280-26-051852.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-051852 |
| 2026-06-23 | 08:35 ET | [8-K](/filings/0001628280-26-044806.md) | 5.07 Shareholder vote results | 0001628280-26-044806 |
| 2026-06-16 | 08:39 ET | [8-K](/filings/0001628280-26-043431.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-043431 |
| 2026-05-22 | 17:20 ET | [SCHEDULE 13D/A](/filings/0000919574-26-003685.md) | Ownership report, active investor, amended | 0000919574-26-003685 |
| 2026-05-15 | 19:05 ET | [SCHEDULE 13D/A](/filings/0001011438-26-000350.md) | Ownership report, active investor, amended | 0001011438-26-000350 |
| 2026-05-11 | 21:20 ET | [SCHEDULE 13D/A](/filings/0001011438-26-000275.md) | Ownership report, active investor, amended | 0001011438-26-000275 |
| 2026-05-04 | 16:15 ET | [10-Q](/filings/0001818331-26-000041.md) | Quarterly report, period 2026-03-31 | 0001818331-26-000041 |
| 2026-05-04 | 16:09 ET | [8-K](/filings/0001818331-26-000039.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001818331-26-000039 |
| 2026-04-30 | 16:09 ET | [DEF 14A](/filings/0001818331-26-000030.md) | Proxy statement, period 2025-12-31 | 0001818331-26-000030 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001818331-26-000015.md), filed Feb 23, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/1c65ebb9-e4aa-4d44-a487-e75571cfe866)

## About the filer

- CIK: 1818331
- Tickers: WGS
- Exchange: Nasdaq
- SIC code: 8000 Services-Health Services
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.